Here, sortilin and syndecan-1 were selected as therapeutic targets for prostate cancer due to their capacity to recognize different morphologies in cancer tissue, as well as their specific regulatory/functional roles in cell metabolism [40,41,44,51,52,53,54]. The gene discussed is SDC1; the disease is prostate cancer.